{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:18:33Z","timestamp":1794129513850,"version":"4.8.0"},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Immune checkpoint inhibitors target checkpoint proteins with the goal of reinvigorating the host immune system and thus restoring antitumor response. With the dramatic increase in the use of checkpoint inhibitors for cancer treatment, surgical pathologists have assumed a major role in predicting the therapeutic efficacy (score based on programmed cell death ligand 1 immunohistochemistry and mismatch repair protein loss) as well as diagnosing the complications associated with these medications. Immune-related adverse events (irAEs) manifest as histologic changes seen in both the upper and lower gastrointestinal tract, and when viewed in isolation, may be morphologically indistinguishable from a wide range of diseases including infections, celiac disease, and inflammatory bowel disease, among others. Evaluation of biopsies from both the upper and lower gastrointestinal tract can aid in the distinction of gastrointestinal irAEs from their mimics. In the liver, the histologic changes of hepatic irAEs overlap with de novo diseases associated with hepatitic and cholangitic patterns of injury. The diagnosis of irAEs requires communication and collaboration from the pathologist, oncologist, and gastroenterologist. This review provides a background framework and illustrates the histologic features and differential diagnosis of gastrointestinal and hepatic irAEs.<\/jats:p>","DOI":"10.1097\/pas.0000000000001730","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T20:22:44Z","timestamp":1621455764000},"page":"e15-e26","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["Histopathology of Gastrointestinal Immune-related Adverse Events"],"prefix":"10.1097","volume":"46","author":[{"given":"M. Lisa","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s10120-018-00909-5","article-title":"Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study","volume":"22","author":"Bang","year":"2019","journal-title":"Gastric Cancer"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and Safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the Phase 2 KEYNOTE-180 Study","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1634\/theoncologist.2018-0221","article-title":"FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1","volume":"24","author":"Fashoyin-Aje","year":"2019","journal-title":"Oncologist"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"771","DOI":"10.21037\/jgo.2016.08.06","article-title":"The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1","volume":"7","author":"Jin","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.path.2016.04.007","article-title":"Molecular evaluation of colorectal adenocarcinoma: current practice and emerging concepts","volume":"9","author":"Nowak","year":"2016","journal-title":"Surg Pathol Clin"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00535-019-01620-7","article-title":"Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers","volume":"55","author":"Eso","year":"2020","journal-title":"J Gastroenterol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/PAS.0000000000001220","article-title":"Interobserver agreement for mismatch repair protein immunohistochemistry in endometrial and nonserous, nonmucinous ovarian carcinomas","volume":"43","author":"Sari","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/his.14233","article-title":"Identifying mismatch repair-deficient colon cancer: near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series","volume":"78","author":"Loughrey","year":"2021","journal-title":"Histopathology"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4143\/crt.2019.718","article-title":"PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs","volume":"52","author":"Park","year":"2020","journal-title":"Cancer Res Treat"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jtho.2020.03.029","article-title":"Canadian Multicenter Project on Standardization of programmed death-ligand 1 immunohistochemistry 22C3 laboratory-developed tests for pembrolizumab therapy in NSCLC","volume":"15","author":"Torlakovic","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fimmu.2017.01547","article-title":"Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract","volume":"8","author":"Dougan","year":"2017","journal-title":"Front Immunol"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","article-title":"Diagnosis and management of hepatitis in patients on checkpoint blockade","volume":"23","author":"Reynolds","year":"2018","journal-title":"Oncologist"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"e1344805","DOI":"10.1080\/2162402X.2017.1344805","article-title":"Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"Oncologist"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11894-020-0752-z","article-title":"Gastrointestinal and hepatic complications of immunotherapy: current management and future perspectives","volume":"22","author":"Dougan","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","article-title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","volume":"28","author":"Collins","year":"2017","journal-title":"Ann Oncol"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.14309\/crj.2017.57","article-title":"Severe esophagitis and gastritis from nivolumab therapy","volume":"4","author":"Boike","year":"2017","journal-title":"ACG Case Rep J"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40425-018-0481-0","article-title":"A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy","volume":"6","author":"Horisberger","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"S1031","DOI":"10.14309\/00000434-201810001-01814","article-title":"Immune-related esophagitis and duodenitis secondary to nivolumab-ipilimumab combination therapy","volume":"113","author":"Wang","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"R40-20250608","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1111\/1346-8138.15421","article-title":"Ulcerative esophagitis associated with combined nivolumab and ipilimumab therapy","volume":"47","author":"Endo","year":"2020","journal-title":"J Dermatol"},{"key":"R41-20250608","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5858\/arpa.2020-0070-RA","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy","volume":"145","author":"Patil","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"R42-20250608","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/nyas.13260","article-title":"Lymphocytic esophagitis: a histologic pattern with emerging clinical ramifications","volume":"1381","author":"Lisovsky","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"R43-20250608","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1309\/7LABLGY08UEM3H26","article-title":"Lymphocytic esophagitis: a histologic subset of chronic esophagitis","volume":"125","author":"Rubio","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"R44-20250608","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/PAS.0000000000001394","article-title":"Lymphocyte-predominant esophagitis: a distinct and likely immune-mediated disorder encompassing lymphocytic and lichenoid esophagitis","volume":"44","author":"Pittman","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R45-20250608","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-018-0332-z","article-title":"Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab","volume":"6","author":"Acero Brand","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R46-20250608","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jtho.2016.07.018","article-title":"Response to pembrolizumab in a patient with relapsing thymoma","volume":"11","author":"Zander","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R47-20250608","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/his.13963","article-title":"Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies","volume":"76","author":"Zhang","year":"2020","journal-title":"Histopathology"},{"key":"R48-20250608","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"R49-20250608","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/his.14029","article-title":"Morphological spectrum of immune check-point inhibitor therapy-associated gastritis","volume":"76","author":"Johncilla","year":"2020","journal-title":"Histopathology"},{"key":"R50-20250608","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5858\/arpa.2019-0700-OA","article-title":"Immune checkpoint inhibitor\u2013induced upper gastrointestinal tract inflammation shows morphologic similarities to, but is immunologically distinct from, Helicobacter pylori gastritis and celiac disease","volume":"145","author":"Irshaid","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"R51-20250608","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/his.13118","article-title":"PD-1 inhibitor gastroenterocolitis: case series and appraisal of \u201cimmunomodulatory gastroenterocolitis\u201d","volume":"70","author":"Gonzalez","year":"2017","journal-title":"Histopathology"},{"key":"R52-20250608","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/CMR.0000000000000502","article-title":"Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma","volume":"28","author":"Yip","year":"2018","journal-title":"Melanoma Res"},{"key":"R53-20250608","doi-asserted-by":"crossref","first-page":"e000958","DOI":"10.1136\/jitc-2020-000958","article-title":"Immune checkpoint inhibitor-associated celiac disease","volume":"8","author":"Badran","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R54-20250608","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/jclinpath-2018-205143","article-title":"Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists\u2019 perspective","volume":"71","author":"Karamchandani","year":"2018","journal-title":"J Clin Pathol"},{"key":"R55-20250608","doi-asserted-by":"crossref","first-page":"e000451","DOI":"10.1136\/jitc-2019-000451","article-title":"Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis","volume":"8","author":"Mooradian","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R56-20250608","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune checkpoint inhibitor-induced colitis: a comprehensive review","volume":"7","author":"Som","year":"2019","journal-title":"World J Clin Cases"},{"key":"R57-20250608","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","article-title":"Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies","volume":"41","author":"Chen","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R58-20250608","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/his.14248","article-title":"Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis","volume":"78","author":"Isidro","year":"2021","journal-title":"Histopathology"},{"key":"R59-20250608","first-page":"28","article-title":"Infectious colitis associated with ipilimumab therapy","volume":"7","author":"McCutcheon","year":"2014","journal-title":"Gastroenterol Res Pract"},{"key":"R60-20250608","doi-asserted-by":"crossref","first-page":"e1128611","DOI":"10.1080\/2162402X.2015.1128611","article-title":"Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis","volume":"5","author":"Lankes","year":"2016","journal-title":"Oncoimmunology"},{"key":"R61-20250608","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R62-20250608","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R63-20250608","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000525","article-title":"Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides","volume":"39","author":"Louie","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R64-20250608","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.humpath.2009.04.001","article-title":"Pathology of graft-versus-host disease in the gastrointestinal tract","volume":"40","author":"Washington","year":"2009","journal-title":"Hum Pathol"},{"key":"R65-20250608","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/PAS.0000000000000317","article-title":"Gastrointestinal biopsy findings of autoimmune enteropathy: a review of 25 cases","volume":"38","author":"Masia","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R66-20250608","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors","volume":"115","author":"Miller","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R67-20250608","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41379-020-00653-1","article-title":"Liver biopsy findings in patients on immune checkpoint inhibitors","volume":"34","author":"Cohen","year":"2020","journal-title":"Mod Pathol"},{"key":"R68-20250608","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jhep.2018.08.014","article-title":"Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: a retrospective study","volume":"69","author":"Parlati","year":"2018","journal-title":"J Hepatol"},{"key":"R69-20250608","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/hep.30157","article-title":"Nodular regenerative hyperplasia associated with immune checkpoint blockade","volume":"68","author":"LoPiccolo","year":"2018","journal-title":"Hepatology"},{"key":"R70-20250608","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"R71-20250608","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/his.14000","article-title":"Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen","year":"2020","journal-title":"Histopathology"},{"key":"R72-20250608","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","article-title":"Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma","volume":"57","author":"Kleiner","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R73-20250608","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"R74-20250608","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R75-20250608","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/gastro\/goz044","article-title":"Histologic patterns of liver injury induced by anti-PD-1 therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"Gastroenterol Rep"},{"key":"R76-20250608","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.pathol.2017.07.010","article-title":"Histopathology of pembrolizumab-induced hepatitis: a case report","volume":"49","author":"Aivazian","year":"2017","journal-title":"Pathology"},{"key":"R77-20250608","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","article-title":"Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis","volume":"41","author":"Everett","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R78-20250608","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/hepr.13329","article-title":"Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work","volume":"49","author":"Koya","year":"2019","journal-title":"Hepatol Res"},{"key":"R79-20250608","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2169\/internalmedicine.1981-18","article-title":"Efficacy and safety of chemotherapy following anti-PD-1 antibody therapy for gastric cancer: a case of sclerosing cholangitis","volume":"58","author":"Kono","year":"2019","journal-title":"Intern Med"},{"key":"R80-20250608","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.gtc.2017.01.001","article-title":"IgG4-related disease and the liver","volume":"46","author":"Chen","year":"2017","journal-title":"Gastroenterol Clin North Am"},{"key":"R81-20250608","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/modpathol.2009.94","article-title":"IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material","volume":"22","author":"Deshpande","year":"2009","journal-title":"Mod Pathol"},{"key":"R82-20250608","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:05:26Z","timestamp":1749416726000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001730"}},"subtitle":["A Practical Review for the Practicing Pathologist"],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001730","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,13]]}}}